文献速递免疫规划卫生政策与健康促进

微阵列贴片疫苗接种(MAPVac)量表效度验证:测量安全性、可用性与可接受性感知

Validation of the Microarray Patch for Vaccination (MAPVac) scale to measure the perceptions of safety, usability, and acceptability.
PubMed 文献 · Vaccine · 2025-07-23

本研究分三阶段开发并验证MAPVac量表,用于测量18岁以上成人对微阵列贴片(MAP)疫苗安全性、可用性与可接受性的感知。最终量表含20个条目、四因子结构,内部一致性高(Cronbach's alpha=0.90),重测相关性中等(Spearman's r=0.40-0.61)。

要点

  • MAPVac量表最终含20个条目,经探索性因子分析确定四因子模型。
  • 量表内部一致性高(Cronbach's alpha=0.90),两次施测各条目呈中等正相关(Spearman's r=0.40-0.61)。
  • 该量表可用于评估MAP疫苗的社会与行为学层面,辅助疫苗接种项目制定整合策略。

核心结论

  • MAPVac量表是评估MAP疫苗社会与行为学层面的可靠且有效的方法。
  • 该量表可能 assist 疫苗接种项目制定有效策略以整合MAP并克服接种障碍。

研究设计与样本

  • 研究遵循量表开发与验证的三阶段:阶段1为文献综述与关键利益相关者认知访谈(n=10),并由专家(n=14)对草稿量表进行表面效度与内容效度评分。
  • 阶段2通过进一步认知访谈(n=27)与探索性因子分析确定内容效度,据此增删或调整草稿条目。
  • 阶段3通过至少间隔两周的两次在线调查进行信度检验,以确定参与者得分跨时间的一致性并检验内部一致性。
  • 共206名公众完成在线调查,来自澳大利亚与新西兰(n=92,44.7%)、加拿大(n=87,42.2%)和英国(n=27,13.1%)。

主要发现

  • 草稿量表含32个条目,经专家与关键利益相关者认知访谈评估后,最终MAPVac量表含20个条目。
  • 探索性因子分析确定四因子模型,涵盖对MAP疫苗接种达成预期结果的总体积极态度、MAP递送、自我与非专业人员进行接种、以及包括感知不适在内的副作用。
  • MAPVac量表显示高内部一致性(Cronbach's alpha=0.90),并具有相当的重测信度,所有量表条目在两次施测时均呈中等正相关(Spearman's r=0.40-0.61)。

关键数值与推荐

  • 最终MAPVac量表含20个条目,四因子结构。
  • 内部一致性Cronbach's alpha=0.90。
  • 重测相关性Spearman's r=0.40-0.61。

临床怎么用

  • 作者认为该量表可能 assist 疫苗接种项目制定有效策略以整合MAP并克服接种障碍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vaccination is a crucial element of public and population health. Microarray patches (MAPs) may improve vaccine uptake due to reduced pain, being needle-free, enhanced thermostability, and potential for self or lay administration. We aimed to validate a scale that measures perceptions of MAP vaccine safety, usability, and acceptability in adults aged 18+. METHODS: This study followed the three phases of scale development and validation. Phase 1 comprised a literature review and key stakeholder cognitive interviews (n = 10) to identify potential and additional scale items. Experts (n = 14) scored the draft scale for face and content validity. In phase 2 further cognitive interviews (n = 27) and exploratory factor analyses determined content validity, informing the addition, adjustment, or deletion of draft items. In phase 3 reliability testing was undertaken by administering two online surveys at least two weeks apart to determine the consistency of participant scores across time and to examine internal consistency. RESULTS: A draft 32-item scale was developed and assessed by experts and key stakeholder cognitive interviews. The final 'MAPVac' scale consisted of 20 items. A total of 206 participants from the general public completed online surveys across Australia and New Zealand (n = 92, 44.7 %), Canada (n = 87, 42.2 %), and the United Kingdom (n = 27, 13.1 %). A four-factor model was determined by exploratory factor analysis, which encompassed general positive attitude questions around MAP vaccination achieving its desired outcome, MAP delivery, self and lay administration, and side effects including perceived discomfort. The MAPVac scale demonstrated high internal consistency (Cronbach's alpha = 0.90) and considerable repeatability, with all scale items demonstrating moderate positive correlations at both administrations (Spearman's r = 0.40-0.61). CONCLUSION: The MAPVac scale is a reliable and valid approach to assessing MAP vaccines' social and behavioural aspects. This scale may assist vaccination programs in developing effective strategies for integrating MAPs and overcoming barriers to vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Berger MN, Mathieu E, Bin YS, et al. Validation of the Microarray Patch for Vaccination (MAPVac) scale to measure the perceptions of safety, usability, and acceptability. Vaccine. 2025. PMID: 40706510. doi:10.1016/j.vaccine.2025.127538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。